Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

about

Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system.Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer

P2860

Q39066090-8745F0B3-80E4-4082-B68B-6814B344B9B1 Q55021294-1EAA81A0-099D-48C3-B84D-BEDA98951AB2 Q58726253-894052CB-4D99-464B-B888-868E5D399BD3

P2860

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Item

http://www.wikidata.org/entity/Q42282846

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Dual Constant Domain-Fab: A no ...... of a Met therapeutic antibody.

@en

Dual Constant Domain-Fab: A no ...... of a Met therapeutic antibody.

@nl

type

Item

label

Dual Constant Domain-Fab: A no ...... of a Met therapeutic antibody.

@en

Dual Constant Domain-Fab: A no ...... of a Met therapeutic antibody.

@nl

prefLabel

Dual Constant Domain-Fab: A no ...... of a Met therapeutic antibody.

@en

Dual Constant Domain-Fab: A no ...... of a Met therapeutic antibody.

@nl

P1476

Dual Constant Domain-Fab: A no ...... of a Met therapeutic antibody

@en

P2093

Cristina Chiriaco

http://www.w3.org/2001/XMLSchema#string

Lara Fontani

http://www.w3.org/2001/XMLSchema#string

Paola Milla

http://www.w3.org/2001/XMLSchema#string

Paolo Michieli

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

P304

938-948

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MOLONC.2016.03.004

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27103110

http://www.w3.org/2001/XMLSchema#string

P932

5423175

http://www.w3.org/2001/XMLSchema#string

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

about

P2860

P2860

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932